Get the Stockscreener App
2.36
0.43%
0.010
After Hours:
2.36
Neurobo Pharmaceuticals Inc stock is traded at $2.36, with a volume of 13,013.
It is up +0.43% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$2.35
Open:
$2.35
24h Volume:
13,013
Relative Volume:
0.30
Market Cap:
$20.33M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.9916
EPS:
-2.38
Net Cash Flow:
$-10.85M
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
-30.59%
1Y Performance:
-55.47%
1-Day Range:
$2.32
$2.44
1-Week Range:
$2.32
$2.44
52-Week Range:
$2.08
$6.7499
Neurobo Pharmaceuticals Inc Stock (NRBO) Company Profile
Name
Neurobo Pharmaceuticals Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE, MA
Compare NRBO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRBO
Neurobo Pharmaceuticals Inc
|
2.36 | 20.33M | 0 | -12.47M | -10.85M | -2.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Neurobo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
Neurobo Pharmaceuticals Inc Stock (NRBO) Latest News
NeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Price Up 1.5% – Still a Buy? - Defense World
Financial Survey: NeuroBo Pharmaceuticals (NASDAQ:NRBO) & Northwest Biotherapeutics (OTCMKTS:NWBO) - Defense World
NeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Price Up 2.9% – Here’s Why - Defense World
NeuroBo Pharmaceuticals : Statement of Changes in Beneficial OwnershipForm 4 - Marketscreener.com
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking - The Globe and Mail
NeuroBo Pharmaceuticals (NASDAQ:NRBO) Trading Down 2.8% – What’s Next? - Defense World
NeuroBo Pharmaceuticals : Reports Third Quarter 2021 Financial ResultsForm 8-K - Marketscreener.com
Reviewing InterCure (NASDAQ:INCR) & NeuroBo Pharmaceuticals (NASDAQ:NRBO) - Defense World
Diabetic Nephropathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, NeuroBo Pharma, Don-A ST, MThera Pharma , Grünenthal, Averitas Pharma, Daiichi Sankyo - Barchart
MTVA stock touches 52-week low at $2.04 amid market challenges - Investing.com Canada
MTVA stock touches 52-week low at $2.04 amid market challenges By Investing.com - Investing.com South Africa
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Dong-A ST Co., Ltd. - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Decides to Discontinue Its Clinical Development of ANA001 (Niclosamide) and Clinical Development of Gemcabene for the Treatment of COVID-19 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces CEO Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces the Appointment of Current Board Member, Hyung Heon ("H.H.") Kim as the Company's President, Principal Executive Officer, and Principal Accounting Officer - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
NeuroBo Pharmaceuticals Announces Management Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Exclusive License Agreement with MThera Pharma Co., Ltd. for NB-01 - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Elects Hyung Heon Kim and Andrew I. Koven to Board of Directors - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NeuroBo Pharmaceuticals Reveals Promising Therapeutic Developments - TipRanks
NeuroBo Pharmaceuticals rebrands to become MetaVia - FiercePharma
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA By Investing.com - Investing.com Canada
NeuroBo Pharmaceuticals announces relignment, change name - TipRanks
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA - Investing.com
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes - TipRanks
Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 - StreetInsider.com
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
NeuroBo Pharma Rebrands as MetaVia, Advances $70M Cardiometabolic Pipeline - StockTitan
ARMISTICE CAPITAL, LLC Acquires Shares in NeuroBo Pharmaceuticals Inc - GuruFocus.com
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 - Smartkarma
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - cnhinews.com
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Finansavisen - Finansavisen
NRBO stock touches 52-week low at $2.55 amid market challenges - Investing.com
NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation - TipRanks
Neurobo Pharmaceuticals Inc Stock (NRBO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):